title: PLCε signaling in cancer.
abstract: OBJECTIVE
  As one of the members of the PLC family, the phosphoinositide-specific phospholipase Cε (PLCε) has been shown to play pivotal roles in multiple signal pathways and control a variety of cellular functions. A number of studies have shown that aberrant regulation of PLCε was involved in various types of animal and human cancer. However, the role of PLCε in cancer remains elusive. In this review, we provide an overview of the PLCε, especially its roles in multiple signal pathways, and summarize the recent findings that highlight the roles of PLCε in carcinogenesis and cancer progression, making an avenue to provide a novel therapeutic strategy for the treatment of cancer.
  
  
  METHODS
  A literature search mainly paying attention to the network of PLCε involved in tumorigenesis and development was performed in electronic databases.
  
  
  RESULTS
  PLCε plays a key role in medicating the development and progression of human cancers with highest potency to be a target of cancer prevention and treatment.
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China.
authors.forename: Rui-Yan
authors.initials: RY
authors.lastname: Zhang
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China.
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Du
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China.
authors.forename: Ying-Chun
authors.initials: YC
authors.lastname: Zhang
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China. jnzheng@xzmc.edu.cn.|Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221002, People's Republic of China. jnzheng@xzmc.edu.cn.|Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical College, Xuzhou, 221002, Jiangsu, People's Republic of China. jnzheng@xzmc.edu.cn.
authors.forename: Jun-Nian
authors.initials: JN
authors.lastname: Zheng
authors.affiliation: Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, 84 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China. dspei@xzmc.edu.cn.
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Pei
mesh_terms: D000818:Animals; D017209:Apoptosis; D016923:Cell Death; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D018450:Disease Progression; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D009369:Neoplasms / Q000378:metabolism* / Q000473:pathology*; D054801:Phosphoinositide Phospholipase C / Q000378:metabolism*; D015398:Signal Transduction; D018631:ras Proteins / Q000378:metabolism
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors; D054801:Phosphoinositide Phospholipase C; C423320:phospholipase C epsilon; D018631:ras Proteins
keywords: Cancer; EGFR; NF-κB; Phospholipase Cε; Ras; Signal pathway